We are live on ! Find out more
SYK icon

Stryker

277.33 USD
+0.36
0.13%
At close Updated Oct 9, 4:00 PM EDT
Pre-market
After hours
277.70
+0.37
0.13%
1 day
0.13%
5 days
0.66%
1 month
0.7%
3 months
-15.22%
6 months
-18.23%
Year to date
-20.35%
1 year
-25.09%
5 years
7.18%
10 years
135.32%
 

About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Employees: 56,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 42.2%
Neutral 53.1%
Negative 4.7%
Neutral
PRNewsWire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutral
GlobeNewsWire
4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Negative
Investors Business Daily
5 days ago
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Neutral
GlobeNewsWire
5 days ago
Stryker announces leadership succession
Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company's Board at that time.
Stryker announces leadership succession
Positive
Seeking Alpha
6 days ago
Stryker: This Dividend Aristocrat Is Finally Cheap Again
Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. SYK demonstrates robust organic sales growth, balanced across geographies and segments, with strong demand and elevated equipment backlogs. Key growth drivers include Mako robotic-assisted procedures, ASC expansion, and Smart Care platform integration, supporting double-digit EPS growth expectations.
Stryker: This Dividend Aristocrat Is Finally Cheap Again
Neutral
Newsfile Corp
8 days ago
SYK INVESTIGATION: Stryker Investors Should Contact Block & Leviton To Learn How They Might Recover Losses
Boston, Massachusetts--(Newsfile Corp. - October 2, 2026) - Block & Leviton is investigating Stryker Corporation (NYSE: SYK) for potential securities law violations. Investors who have lost money in their Stryker investment should contact the firm to learn more about how they might recover those losses.
SYK INVESTIGATION: Stryker Investors Should Contact Block & Leviton To Learn How They Might Recover Losses
Positive
Zacks Investment Research
8 days ago
GEHC vs. SYK: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
GEHC vs. SYK: Which Stock Should Value Investors Buy Now?
Neutral
PRNewsWire
9 days ago
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
Neutral
PRNewsWire
10 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutral
GlobeNewsWire
10 days ago
Stryker to announce third quarter 2026 financial results
Portage, Michigan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, October 29, 2026, to discuss its third quarter 2026 financial results.
Stryker to announce third quarter 2026 financial results
Price charts implemented using Lightweight Charts™